Compare
Prokidney Corp. vs Pelthos Therapeutics Inc. vs C4 Therapeutics, Inc. vs Invivyd, Inc.
| Latest fiscal year | Prokidney Corp. PROK | Pelthos Therapeutics Inc. PTHS | C4 Therapeutics, Inc. CCCC | Invivyd, Inc. IVVD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $893.0K | $16.80M | $35.95M | $53.43M |
| Revenue growth (YoY) | n/m | n/a | +1.0% | +110.5% |
| Gross margin | n/a | 76.3% (computed) | n/a | n/a |
| Operating margin | n/m | -193.1% | -320.5% | -104.0% |
| Net margin | n/m | -257.9% | -292.1% | -98.2% |
| Net income | -$151.61M | -$43.32M | -$104.99M | -$52.49M |
| EPS (Diluted) | n/a | -$23.04 | -$1.27 | -$0.30 |
| Operating cash flow | -$120.12M | -$22.59M | -$98.69M | -$58.13M |
| Free cash flow | -$135.31M | -$22.69M | -$99.30M | -$58.29M |
| Cash & equivalents | $108.54M | $17.97M | $74.60M | $226.69M |
| Total assets | $335.57M | $130.40M | $359.07M | $276.88M |
| Total liabilities | $34.78M | $91.52M | $102.49M | $35.34M |
| Shareholders' equity | -$1.01B | $38.88M | $256.59M | $241.54M |
| Return on year-end equity | n/a | -111.4% | -40.9% | -21.7% |
| Shares outstanding | n/a | 3.23M | 96.91M | 281.99M |
Revenue, most recent five fiscal years
| Fiscal year | Prokidney Corp. | Pelthos Therapeutics Inc. | C4 Therapeutics, Inc. | Invivyd, Inc. |
|---|---|---|---|---|
| Latest | $893.0K Ended 2025-12-31 | $16.80M Ended 2025-12-31 | $35.95M Ended 2025-12-31 | $53.43M Ended 2025-12-31 |
| 1 year earlier | $76.0K Ended 2024-12-31 | $0 Ended 2024-12-31 | $35.58M Ended 2024-12-31 | $25.38M Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | n/a | $20.76M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | $0 Ended 2022-12-31 | n/a | $31.10M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | $45.78M Ended 2021-12-31 | n/a |